Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Bought by Teacher Retirement System of Texas

Teacher Retirement System of Texas grew its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 27.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,383 shares of the company’s stock after purchasing an additional 1,369 shares during the quarter. Teacher Retirement System of Texas’ holdings in Krystal Biotech were worth $1,000,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in KRYS. US Bancorp DE boosted its holdings in shares of Krystal Biotech by 8.7% in the fourth quarter. US Bancorp DE now owns 1,027 shares of the company’s stock valued at $161,000 after acquiring an additional 82 shares during the period. Crossmark Global Holdings Inc. raised its position in Krystal Biotech by 5.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company’s stock valued at $362,000 after purchasing an additional 121 shares during the last quarter. Perigon Wealth Management LLC boosted its stake in Krystal Biotech by 1.5% during the 4th quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company’s stock worth $1,200,000 after purchasing an additional 123 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Krystal Biotech by 3.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,614 shares of the company’s stock worth $840,000 after purchasing an additional 153 shares during the last quarter. Finally, Xponance Inc. increased its stake in Krystal Biotech by 9.5% in the fourth quarter. Xponance Inc. now owns 1,785 shares of the company’s stock valued at $280,000 after purchasing an additional 155 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on KRYS shares. Citigroup increased their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. Chardan Capital boosted their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday, February 20th. HC Wainwright restated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research note on Friday, February 28th. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $220.00.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Krystal Biotech Stock Performance

NASDAQ:KRYS opened at $183.92 on Friday. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34. The stock has a fifty day moving average price of $170.82 and a two-hundred day moving average price of $173.73. The stock has a market capitalization of $5.30 billion, a price-to-earnings ratio of 61.51 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business’s revenue was up 116.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.30 EPS. On average, analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).